Early TIPS for Ascites Study
This study has been terminated.
(Slow enrollment)
Sponsor:
W.L.Gore & Associates
Information provided by (Responsible Party):
W.L.Gore & Associates
ClinicalTrials.gov Identifier:
NCT01236339
First received: November 4, 2010
Last updated: March 20, 2013
Last verified: March 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to demonstrate that TIPS with the GORE® VIATORR® TIPS Endoprosthesis improves transplant-free survival compared to LVP alone in patients who have cirrhosis of the liver with portal hypertension and difficult to treat ascites.
| Condition | Intervention |
|---|---|
|
Liver Cirrhosis Portal Hypertension Ascites |
Device: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis Procedure: LVP |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The GORE® VIATORR® TIPS Endoprosthesis Versus Large-Volume Paracentesis for the Treatment of Ascites in Patients With Portal Hypertension |
Resource links provided by NLM:
Genetics Home Reference related topics:
North American Indian childhood cirrhosis
U.S. FDA Resources
Further study details as provided by W.L.Gore & Associates:
Primary Outcome Measures:
- Transplant-free Survival [ Time Frame: Through 24 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Overall Survival [ Time Frame: Through 24 months ] [ Designated as safety issue: No ]
- Time to Transplant [ Time Frame: Through 24 months ] [ Designated as safety issue: No ]
- Frequency and Volume of Paracentesis [ Time Frame: Through 24 months ] [ Designated as safety issue: No ]
- Frequency of Hepatic Encephalopathy [ Time Frame: Through 24 months ] [ Designated as safety issue: No ]
- Change in MELD Score [ Time Frame: Baseline, Discharge (if applicable), 30 days, 3, 6, 12, 18, 24 months ] [ Designated as safety issue: No ]
- Change in Quality of Life [ Time Frame: Baseline, 3, 6, 12 months ] [ Designated as safety issue: No ]
- Procedural Success [ Time Frame: Time of TIPS Procedure ] [ Designated as safety issue: No ]
- Liver Disease Complications (Adverse Events) [ Time Frame: Through 24 months ] [ Designated as safety issue: No ]
| Enrollment: | 26 |
| Study Start Date: | December 2010 |
| Estimated Study Completion Date: | June 2015 |
| Estimated Primary Completion Date: | June 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: TIPS
TIPS with GORE® VIATORR® TIPS Endoprosthesis
|
Device: TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
|
| Active Comparator: LVP (Large Volume Paracentesis) |
Procedure: LVP
Large Volume Paracentesis
|
Eligibility| Ages Eligible for Study: | 18 Years to 69 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient has cirrhosis of the liver with portal hypertension
Patient has difficult to treat ascites, defined as at least one of the following:
- Subject requires paracentesis despite treatment with high dose diuretics [at least 80 mg of furosemide (or 2 mg bumetanide) and 200 mg aldactone (or 20 mg amiloride)] within the last 90 days
- Subject requires repeated paracentesis (cumulative volume of at least 10 L removed) within a 45 day period
- Subject requires paracentesis and can not tolerate diuretics due to a documented complication of diuretic therapy
- Patient has a MELD score ≤18 prior to randomization
- Patient is 18 years or older and <70 years old at randomization
- Patient has a creatinine ≤ 2.0 mg/dL
- Patient has a total bilirubin ≤3.0 mg/dL
- Patient has a serum sodium ≥ 130 mmol/L
- Patient is willing and able to comply with all study protocol requirements, including specified follow-up and testing.
- Patient, or legal authorized representative, is willing to provide written informed consent prior to enrollment in the study.
Exclusion Criteria:
- Patient has more than 6 large volume paracenteses of at least 5 liters each within 90 days prior to randomization
- Patient has a history of spontaneous hepatic encephalopathy requiring hospitalization
- Patient has hepatic encephalopathy (grade 2 or greater) not responsive to medical management
- Patient has known hepatocellular carcinoma
- Patient has complete thrombosis of main portal vein
- Patient has known pulmonary hypertension (mean PA pressure > 30 mmHg) based on cardiac ultrasound or catheterization
- Patient has congestive heart failure
- Patient has active bacterial infection
- Patient has symptomatic hepatic hydrothorax requiring repetitive thoracenteses
- Patient has Type 1 hepatorenal syndrome (HRS)
- Patient has Budd-Chiari syndrome
- Patient is contraindicated for TIPS placement
- Patient has had previous TIPS placement
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01236339
Locations
| United States, Arizona | |
| University of Arizona | |
| Tucson, Arizona, United States | |
| United States, California | |
| University of California-Los Angeles | |
| Los Angeles, California, United States | |
| Leland Stanford Junior University | |
| Palo Alto, California, United States | |
| United States, Georgia | |
| Piedmont Hospital, Incorporated | |
| Atlanta, Georgia, United States | |
| United States, Illinois | |
| Northwestern University | |
| Chicago, Illinois, United States | |
| Rush University Medical Center | |
| Chicago, Illinois, United States | |
| United States, Indiana | |
| Indiana University | |
| Indianapolis, Indiana, United States | |
| United States, Kansas | |
| University of Kansas Medical Center Research Institute, Inc. | |
| Kansas City, Kansas, United States | |
| United States, Maryland | |
| University of Maryland-Baltimore | |
| Baltimore, Maryland, United States | |
| United States, Michigan | |
| University of Michigan | |
| Ann Arbor, Michigan, United States | |
| United States, Missouri | |
| University of Washington School of Medicine - Barnes-Jewish Hospital | |
| St Louis, Missouri, United States | |
| United States, New York | |
| Mt. Sinai Medical Center | |
| New York City, New York, United States | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Releigh, North Carolina, United States | |
| United States, Ohio | |
| Cleveland Clinic | |
| Cleveland, Ohio, United States | |
| United States, Oregon | |
| Oregon Health & Science University | |
| Portland, Oregon, United States | |
| United States, Pennsylvania | |
| University of Pennsylvania | |
| Philadelphia, Pennsylvania, United States | |
| United States, Virginia | |
| Virginia Commonwealth University | |
| Richmond, Virginia, United States | |
| Canada, Ontario | |
| Toronto General Hospital | |
| Toronto, Ontario, Canada | |
Sponsors and Collaborators
W.L.Gore & Associates
Investigators
| Principal Investigator: | Thomas Boyer, MD | University of Arizona College of Medicine |
| Principal Investigator: | Ziv Haskal, MD | University of Maryland |
More Information
Additional Information:
Related Info 
No publications provided
| Responsible Party: | W.L.Gore & Associates |
| ClinicalTrials.gov Identifier: | NCT01236339 History of Changes |
| Other Study ID Numbers: | VTR 10-03 |
| Study First Received: | November 4, 2010 |
| Last Updated: | March 20, 2013 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Ascites Hypertension Hypertension, Portal Liver Cirrhosis Fibrosis |
Pathologic Processes Vascular Diseases Cardiovascular Diseases Liver Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013